Wockhardt
BSE: 532300 | NSE: WOCKPHARMA | ISIN: INE049B01025 | Pharmaceuticals
| Company History - Wockhardt | |
YEAR EVENTS
2000 - Wockhardt has launched cardiac drug enalapril maleate in the
US through its
marketing joint venture with Sidmak Laboratories.
- Pharmaceutical major Wockhardt Ltd has set up a corporate
training centre with
modern and state-of-the-art facility under one roof at
Aurangabad.
2001 - Wockhardt Hospitals Ltd, the wholly owned subsidiary of
Wockhardt Ltd, will set up
two cardiac hospitals in Mumbai and Bangalore.
- The Company has terminated its three-year old marketing
alliance with Sidmak
Laboratories, one of the top ten generic pharma
companies in the US.
- Pharma major Wockhardt Ltd. has entered into a strategic
alliance with a Japanese
firm Eisai Company Ltd. to manufacture and market a
neurology drug -- Methycobal.
- Wockhardt Hospitals Ltd, the wholly owned subsidiary of
pharmaceutical major
Wockhardt Ltd, has tied up with four international
health insurance companies to
offer medical cover to non-resident Indians.
- AGM JUNE 8 2001 Wockhardt has launched an innovative and
attractive employee stock option scheme,
ESOP.
- Wockhardt Ltd has introduced an employee stock option
(ESOP) scheme for over 175 employees
in the senior and middle management levels with about
2,00,000 shares being allotted.
2002
-The Hari L Mundra has joined Wockhardt as vice-chairman. Mundra
will spearhead the company's domestic operations which
account for 70 per cent of its turnover.
- Wockhardt Ltd has appointed Mr. Lalit Kumar as Executive Director
on its Corporate Board. Mr. Kumar will spearhead
Wockhardt's International Business covering bulk drug
operations and formulations export, as well as ANDA research and
Intellectual Property Rights.
2003
-Wockhardt restructured its field organization to upgrade its
competitiveness and
productivity.
-Mumbai based wockhardt will hit the domestic market with the first
indigenously
developed insulin soon, in a move to induce turmoil in the market.
-Wockhardt has launched new four speciality hospitals at its Mulund
complex in Mumbai.
-Maharashtra Government decided to terminate its Joint Venture
agreement with
Wockhardt for setting up a super speciality hospital.
-Wockhardt Limited has acquired CP pharmaceuticals(Holdings) Ltd,
along with
its subsidiaries.
-Wockhardt is strengthening its marketing strategies and distribution
system to
unveil human insulin in Indian market.
-Wockhardt Launched Asia's first human recombinant insulin, making
India the
first Asian country to develop, manufacture and market the product.
-Wockhardt Ltd has received USFDA approval for marketing bethanecol
Chloride
tablets in the US.
-Wockhardt baged USFDA approval for Bethanechol
-Baged US approval to sell bethanechol chloride tablets
-Wockhardt Ltd has informed that Mr. JS Khorakiwala who has been on
the board of the company as Executive Director, has resigned from the
directorship with immediate effect.
2004
-Wockhardt Ltd has filed an Investigational New Drug (IND)
application for its new drug for respiratory infections, WCK-1152
- Wockhardt Ltd has acquired German pharmaceutical company esparma
GmbH for a consideration of million (around Rs 49 crore).
-Centre for Drug Evaluation & Research, an arm of the US Food & Drug
Administration (US FDA), has approved the sterile injectable facility
as well as facilities for sterile bulk drugs (active pharmaceutical
ingredient) and formulations spread over three locations in India
-Wockhardt gets USFDA nod for 6 manufacturing units
2005
-Launches of India's first automatic insulin delivery device
specially designed for the convenience of Indian diabetic patients on
February 14, 2005
-Wockhardt forges alliance with Kamineni Group to establish two
world-class heart hospitals in the Hyderabad
-Wockhardt unveils father`s heart network
-Wockhardt receives US FDA approval for marketing cefuroxime axetil
in the US market
-Wockhardt unveils new generation hepatitis A vaccine
-Wockhardt rolls out new Hepatitis A vaccine
2006
-Wockhardt's Waluj plant approved by US FDA
2007
-Wockhardt signs in-licensing pact with Crawford Healthcare of UK.
-Wockhardt Ltd has appointed Mr. Rajiv B Gandhi as Director- Finance
& Information for a period of five years effective from February 22,
2007, subject to the approval of shareholders.
-Wockhardt Ltd has announced US FDA approval for marketing Ketorolac
anti-inflammatory injection in the US market, its third US FDA
approval in the last ten days.
- Wockhardt Ltd on May 03, 2007 has announced the acquisition of
Negma Laboratories, the fourth largest independent, integrated
pharmaceutical group in France with sales of $ 150 million. The
Company has acquired Negma Laboratories in an all-cash deal worth $
265 million. The transaction is valued at 1.8 times the sales and 9.7
times the EBITDA.
|
|
![]() | |
| Source : Religare Technova | |
![]() |




Online










